Page 3 - Naomi Eichenbaum News Today

SAN DIEGO, May 11, 2023 -- Travere Therapeutics, Inc. today announced that on May 10, 2023, the Compensation Committee of its Board of Directors granted inducement equity grants to six new... | May 11, 2023

Operator: Good day, and welcome to the Travere Therapeutics First Quarter 2023 Financial Results and Corporate Update Conference Call. Todays conference is being recorded.

The DUPLEX Study did not achieve the primary efficacy eGFR slope endpoint over 108 weeks of treatment Secondary and topline exploratory endpoints trended favorably for sparsentan Treatment with... | May 1, 2023

The DUPLEX Study did not achieve the primary efficacy eGFR slope endpoint over 108 weeks of treatment Secondary and topline exploratory endpoints trended...

SAN DIEGO, April 13, 2023 -- Travere Therapeutics, Inc. today announced that on April 10, 2023, the Compensation Committee of its Board of Directors granted inducement equity grants to five... | April 13, 2023

FILSPARI demonstrated a statistically significant, rapid, and sustained decline of proteinuria compared to the active control...

SAN DIEGO, April 01, 2023 -- Travere Therapeutics, Inc. today announced publication in The Lancet of the interim analysis of efficacy and safety data from the ongoing pivotal, Phase 3 PROTECT... | April 1, 2023

SAN DIEGO, April 01, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced publication in The Lancet of the interim analysis of efficacy and safety data from the ongoing pivotal

SAN DIEGO, March 28, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will participate in the following upcoming conferences: Guggenheim Healthcare Talks | Genomic Medicines and Rare Disease Day...

SAN DIEGO, March 23, 2023 -- Travere Therapeutics, Inc. today announced that the interim analysis of efficacy and safety data from the ongoing Phase 3 PROTECT Study evaluating... | March 23, 2023